Get started
Author

Tiffany F. Chen

Observed names: T. Chen, TIFFANY F. CHEN, Tiffany Chen, Tiffany F Chen
ORCID: 0000-0002-8089-1143
Observed ORCID: 0000-0002-8089-1143
OpenAlex ID: A5074745433
Protein Engineering and Selection Using Yeast Surface Display
2015 · Alessandro Angelini, Tiffany F. Chen, et al. · Methods in molecular biology · 112
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
2021 · Xuqing Zhang, Mengyao Luo, et al. · Nature Communications · 67
PDF
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes
2024 · Gene I. Uenishi, Marko Repic, et al. · JCI Insight · 64
PDF
Engineering Fibronectin-Based Binding Proteins by Yeast Surface Display
2013 · Tiffany F Chen, Seymour de Picciotto, et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 58
Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression
2012 · Jamie B. Spangler, Mandana T. Manzari, et al. · Journal of Molecular Biology · 39
Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs
2017 · Tiffany F. Chen, Stephen L. Sazinsky, et al. · Journal of Molecular Biology · 19
Role of Dimerization in the Catalytic Properties of the Escherichia coli Disulfide Isomerase DsbC
2009 · Silvia A. Arredondo, Tiffany F. Chen, et al. · Journal of Biological Chemistry · 18
PDF
Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types
2018 · Tiffany F. Chen, Kevin K. Li, et al. · Journal of Molecular Biology · 9
PDF
Engineering New Protein–Protein Interactions on the β‐Propeller Fold by Yeast Cell Surface Display
2013 · Keya Zhang, Heng Li, et al. · ChemBioChem · 9
A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.
2021 · Johanna C. Bendell, Alexander I. Spira, et al. · Journal of Clinical Oncology · 3
Abstract PO044: RTX-321, an allogeneic red blood cell-based artificial antigen presenting cell, expressing MHC I-peptide, 4-1BBL and IL-12, engages primary human HPV-specific T cells and boosts other general immune responses
2021 · Mengyao Luo, Shamael S. Dastagir, et al. · Cancer Immunology Research · 2
Abstract 3260: Engineered red-cell therapeutics (RCT) as artificial antigen presenting cells promotein vivoexpansion and anti-tumor activity of antigen specific T cells
2019 · Xuqing Zhang, Shamael R. Dastagir, et al. · Immunology · 2
Engineered Erythrocytes As an Anti-Tumor Therapy through Induction of Apoptosis or Immune-Checkpoint Inhibition
2016 · Sivan Elloul, Claire Depew, et al. · Blood · 2
An allogeneic CD19 targeted Engineered Treg approach for treating B cell mediated autoimmune diseases 2260315
2026 · Payam Zarin, Christopher Moore, et al. · The Journal of Immunology · 1
Abstract B062: Enabling the rapid generation of allogeneic artificial antigen presenting cell (aAPC) Red Cell Therapeutics with a loadable MHC system
2019 · Christopher L Moore, Sneha Pawar, et al. · Molecular Cancer Therapeutics · 1
Abstract 3260: Engineered red-cell therapeutics (RCT) as artificial antigen presenting cells promote in vivo expansion and anti-tumor activity of antigen specific T cells
2019 · Xuqing Zhang, Shamael R. Dastagir, et al. · Cancer Research · 1
Regulatory T cell function and engineering for next generation cell therapies
2026 · Nathan W. Zammit, Martina Sassone-Corsi, et al. · Frontiers in Immunology
PDF
CD19 CAR Engineered T Regulatory Cells Promote Durable Immune Tolerance in Experimental Systemic Lupus Erythematosus
2026 · Travis Drow, Matteo Doglio, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
ST2 enforces a ‘repair-ready’ Treg phenotype that homes to and ameliorates neuroinflammation 2260164
2026 · Nathan Zammit, Maegan Hoover, et al. · The Journal of Immunology
Modular engineering of Tregs for the treatment of inflammatory and autoimmune diseases 2259867
2026 · Payam Zarin, Gene Uenishi, et al. · The Journal of Immunology
GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease 2251383
2026 · Martina Sassone-Corsi, Jennifer Yam, et al. · The Journal of Immunology
PDF
Allogeneic Tissue Tregs Improve Disease Outcome in Models of Acute Lung and Kidney Injury 2259889
2026 · Payam Zarin, Maegan Hoover, et al. · The Journal of Immunology
Adoptive transfer of allogeneic murine Engineered Regulatory T cells ameliorates disease in models of ischemic stroke and acute lung injury 3688
2025 · Payam Zarin, Maegan Hoover, et al. · The Journal of Immunology
PDF
CAR19 EngTregs offer broad capacity to modulate immune tolerance and improve safety in B and T cell mediated autoimmune disorders 3850
2025 · Victoria L. DeVault, Matteo Doglio, et al. · The Journal of Immunology
PDF
Engineered Tissue Tregs ameliorate inflammatory and ischemic diseases 3661
2025 · Maegan Hoover, Priya Saikumar Lakshmi, et al. · The Journal of Immunology
PDF
Works count: 35
Citation count: 407
H-index: 9
I10-index: 7
Year
Topic
Type